현장 진료용 미들웨어 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the point-of-Care middleware market size was valued at USD 0.45 billion in 2025 and is estimated to grow from USD 0.57 billion in 2026 to reach USD 1.06 billion by 2031, at a CAGR of 13.35% during the forecast period (2026-2031).

This report is Segmented by Deployment Mode (Cloud-Based, On-Premise, Hybrid), Application (Glucose Monitoring, Infectious Disease, Coagulation, Urinalysis, Cardiometabolic, Cancer Markers, Hematology, and More), End User (Hospitals and Critical Care Units, Diagnostic Centers, Clinics and More), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Point-of-Care Middleware Market Trends and Insights

Real-time POCT to EHR/LIS Integration Eliminates Clinical Data Latency

The point-of-care middleware market continues to draw its strongest support from the need to replace manual POCT transcription with automated and bidirectional result exchange across instruments, EHR systems, and laboratory platforms. That shift matters because transcription delays and mismatched patient records can weaken the clinical value of near-patient testing in high-volume care settings. Abbott stated that its point-of-care data management environment captures 225 million test results each year and supports more than 80,000 meters and devices that run patient tests every day across its connected base.

Once a health system has mapped POCT flows to specific HL7 v2.x or FHIR R4 message structures, a move to another middleware vendor usually requires broad interface revalidation across departments and sites. That process creates durable switching costs, which is why the point-of-care middleware market tends to show strong incumbent retention even when hospitals review technology stacks. The same integration pressure is reinforced by U.S. interoperability policy, which keeps compliant data exchange close to the center of purchasing decisions for connected diagnostic software.

Cloud-based Fleet Management Reshapes POC Economics at Scale

The point-of-care middleware market is also being reshaped by the limits of older on-premise architectures when health systems manage large fleets of devices across hospitals, clinics, and off-site locations. TELCOR reported that its QML middleware connects more than 2,700 hospitals and ambulatory locations, showing how centralized management has become a practical requirement in multi-site POCT operations. Siemens Healthineers stated that its POCcelerator platform connects more than 250 POCT devices from over 70 manufacturers, while its Ci module provides KPI-level visibility into device performance, QC status, and operator activity.

These capabilities matter because cloud delivery lets vendors update device drivers, quality rules, and compliance settings across all connected sites at once rather than site by site. The point-of-care middleware market therefore gains not only from connectivity demand, but also from the operational savings that come from centralized oversight, better operator control, lower waste, and fewer local server burdens. Operator competency and QC automation fit directly into this shift because centralized platforms can apply common access rules, quiz delivery, and audit documentation without requiring local manual processes at each site.

High Deployment and Interface Costs Constrain Broad Market Penetration

The point-of-care middleware market still faces a meaningful adoption barrier because interface development between middleware, POCT devices, LIS systems, and EHR environments remains technically demanding and expensive. In large multi-vendor hospital environments, upfront interface and validation costs can move into six figures, especially when each device type needs separate testing, documentation, and workflow approval. The FDA's final cybersecurity guidance from February 2026 adds new requirements around SBOM documentation, patch validation planning, and evidence of penetration testing for connected medical devices.

Those obligations raise engineering and implementation costs for vendors, and part of that burden is passed on to customers during deployment and support. The point-of-care middleware market is also affected by bundling behavior from major IVD manufacturers, which often makes open-platform connectivity to competing instruments more expensive for independent diagnostic operators. Public health systems in MEA and South America are more exposed to this issue because procurement budgets often prioritize analyzers and consumables ahead of digital infrastructure, even when the governance case for middleware is clear.

Other drivers and restraints analyzed in the detailed report include:

1. Decentralized Testing Network Expansion Opens New Connectivity Surface
2. ISO 15189:2022 Traceability Requirements Raise the Accreditation Floor
3. Cybersecurity and Data-Privacy Exposure Introduces Deployment Risk

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

On-premise deployment held 51.26% share of the point-of-care middleware market size in 2025, reflecting the large base of hospital installations that were already built around local servers, established IT controls, and data residency preferences. Many hospitals kept these environments because security policy, procurement history, and internal support models were already aligned with locally hosted software. Cloud-based deployment is projected to grow at 15.67% CAGR through 2031, showing that the fastest momentum is now moving toward centrally managed environments for distributed testing networks. That growth is tied to the rising need to support multiple facilities without maintaining local middleware infrastructure at every care site. Hybrid deployment remains the smallest category by share, yet it is drawing attention from organizations that want cloud analytics and centralized management without moving all patient identifiers off local systems.

In practical terms, cloud delivery gives vendors a simpler path to update device drivers, roll out compliance changes, and extend fleet visibility across large networks from one control point. That operating model becomes more attractive as organizations add outpatient clinics, urgent care settings, and community locations that would otherwise need separate server maintenance and local update cycles. Abbott positions AegisPOC as a web-based open platform with secure data center hosting, while Clinisys offers an Orchard point-of-Care SaaS option that supports customers seeking lighter infrastructure demands. Abbott's Australia material also highlights ISO 27001 certification, and that kind of credential is becoming a practical filter in tenders where buyers look for tested governance rather than feature lists alone. Within the point-of-care middleware industry, this leaves on-premise systems in a strong installed position while cloud models gather new demand from customers that value scale, speed of updates, and lower operational overhead.

The point-of-care middleware market is therefore not moving through a simple replacement cycle, but through a gradual shift in what customers expect middleware to manage across space, staff, and compliance tasks. Hybrid models also remain relevant because they offer a middle path for institutions that must respect local governance requirements while still wanting shared analytics and remote fleet visibility. That keeps deployment choice tied closely to customer operating model rather than to a single universal architecture preference. The point-of-care middleware market will likely keep both models active through the forecast period because the installed base changes slowly and the new buying pipeline is more cloud oriented.

Geography Analysis

North America held 38.47% of the point-of-care middleware market share in 2025, making it the largest regional cluster by revenue. The region's lead came from high POCT device density, mature EHR penetration, and a policy environment where interoperability, accreditation, and cybersecurity all influence software buying decisions. Abbott states that its point-of-care data management platform connects more than 50% of U.S. hospitals, which shows how deep the installed base has become in the region. Canada is also contributing to demand, with Saskatchewan Health Authority stating in late 2025 that its POCT program had expanded to 14 locations and had prevented 214 potential emergency department service disruptions. Mexico remains at an earlier stage, but hospital digitization and cross-system connectivity needs still support a gradual expansion path for the point-of-care middleware market across urban care networks. The FDA's 2026 cybersecurity guidance and CLIA-linked oversight help keep middleware spending visible on capital agendas even when provider budgets tighten.

Asia-Pacific is projected to grow at 15.13% CAGR through 2031, which makes it the fastest-growing regional segment in the point-of-care middleware market. Australia offers a clear example of distributed demand, as the government-funded Aboriginal and Torres Strait Islander COVID-19 POC Testing Program operated across 105 clinics, performed 72,624 tests, and recorded a median transmission time of 1.4 hours, with middleware upgrades cited as important when testing rules changed. China and India are also expanding primary care and community testing capacity, which creates more sites that need controlled data flow, operator management, and device traceability. Japan and South Korea add premium demand because hospitals in those systems place higher value on documented quality management and structured data exchange. This leaves Asia-Pacific as the region where volume expansion and governance needs are advancing together rather than separately.

Europe remains a major regional block because Germany, the United Kingdom, and France continue to enforce accreditation and regulated software requirements that make middleware purchases harder to defer. ISO 15189:2022 has widened the traceability and documentation case for POCT oversight, while IVDR 2017/746 keeps qualifying software within a more formal regulatory frame. The Middle East and Africa region is earlier in adoption, yet GCC countries such as Saudi Arabia and the UAE are pushing hospital digitization under national transformation programs that support future middleware uptake. South Africa remains the most developed MEA market because private hospital groups are more active users of accreditation-aligned quality systems. Kenya's PEPFAR-funded Diagnostic Network Optimisation initiative reduced HIV testing turnaround time from 7 days to 2 days across a decentralized referral network, which helps demonstrate the practical value of connected diagnostic oversight in resource-limited settings. South America, led by Brazil and Argentina, is still developing through private hospital and diagnostic chain adoption, while public procurement remains more exposed to budget timing and infrastructure trade-offs.

1. Abbott Laboratories
2. Clinisys, Inc.
3. Danaher Corporation (Radiometer Medical ApS)
4. EKF Diagnostics Holdings plc.
5. Roche
6. Nova Biomedical
7. Relaymed
8. Siemens Healthineers
9. TELCOR Inc.
10. Werfen, S.A.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Real-Time POCT to EHR/LIS Integration
  • 4.2.2 Cloud-Based Fleet Management
  • 4.2.3 Operator Competency and QC Automation
  • 4.2.4 Decentralized Testing Network Expansion
  • 4.2.5 Hospital-At-Home Connectivity Needs
  • 4.2.6 ISO 15189:2022 Traceability Pressure
• 4.3 Market Restraints
  • 4.3.1 High Deployment and Interface Costs
  • 4.3.2 Cybersecurity and Data-Privacy Exposure
  • 4.3.3 Legacy Device Firmware Fragmentation
  • 4.3.4 SBOM and Patch-Validation Burden
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Deployment Mode
  • 5.1.1 Cloud-Based
  • 5.1.2 On-Premise
  • 5.1.3 Hybrid
• 5.2 By Application
  • 5.2.1 Glucose Monitoring
  • 5.2.2 Infectious Disease Devices
  • 5.2.3 Coagulation Monitoring
  • 5.2.4 Urinalysis
  • 5.2.5 Cardiometabolic Monitoring
  • 5.2.6 Cancer Markers
  • 5.2.7 Hematology
  • 5.2.8 Other Applications
• 5.3 By End User
  • 5.3.1 Hospitals and Critical Care Units
  • 5.3.2 Diagnostic Centers
  • 5.3.3 Clinics and Outpatient
  • 5.3.4 Other End Users
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott
  • 6.3.2 Clinisys, Inc.
  • 6.3.3 Danaher Corporation (Radiometer Medical ApS)
  • 6.3.4 EKF Diagnostics Holdings plc.
  • 6.3.5 F. Hoffmann-La Roche Ltd
  • 6.3.6 Nova Biomedical Corporation
  • 6.3.7 Relaymed
  • 6.3.8 Siemens Healthineers AG
  • 6.3.9 TELCOR Inc.
  • 6.3.10 Werfen, S.A.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment